



Contact: Santiago Munne
Location: Livingston, NJ
Email: Smunne@reprogenetics.com
Tel: 973-435-5013
Website: www.reprogenetics.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Biotechnology - Diagnostics

Company Overview: Reprogenetics is a full-service PGD laboratory. We offer aneuploidy screening for all chromosomes using Comparative Genomic Hybridization (CGH) or array CGH (aCGH) and select chromosomes utilizing FISH. Our services include genetic counseling, embryo biopsy, cell fixation/preparation and PGD for translocations, inversions, single gene disorders and HLA matching.

Target Market(s): Currently we target reproductive endocrinologist and infertility clinics, we would like to move to direct consumer marketing and target patients seeking fertility treatment and patients with a history of genetic disorders.

Key Value Drivers

Technology*: Comparative genome hybridization (CGH), array CGH, and SNP arrays, for the purpose of analyzing gametes and embryos to prevent genetic diseases and chromosome abnormalities.

Management

Leadership:

Santiago Munne, President
Jacques Cohen, Scientific Director
Kelly Ketterson, Director, Operations
Dagan Wells, Director, Molecular Laboratory
Pere Colls, Laboratory Director
Jill Fischer, Director, Clinical Genetic Services

Scientific Advisory Board:

David Sable, MD: Managing Director of Special Situations Life Sciences Fund

Product Pipeline